Molecular Partners AG
Molecular Partners AG develops pioneering DARPin therapeutics, including radiopharmaceuticals and tetra-specific T cell engagers for cancer treatment.
Classification
Profile
Funding
Funding details not yet available.
Develops pioneering DARPin therapeutics, including tetra-specific T cell engagers and radiopharmaceuticals, to exceed current cancer treatment limits.
Biopharmaceutical industry partners and cancer patients seeking advanced therapeutic options.
Up-front licensing fees - Payments from partners for access to DARPin candidates · Milestone payments - Clinical, regulatory, and commercial milestones tied to development progress · Royalties on sales - Percentage of net sales once a DARPin therapeutic reaches market
channel partners
Pharmaceutical companies for co-development and licensing of drug candidates
Research and development costs associated with creating novel DARPin-based therapies.
Proprietary DARPin technology platform and specialized expertise in radiopharmaceuticals and immune cell engagers.
Researching and developing DARPin therapeutics, including multi-specific T cell engagers targeting CD33, CD123, CD70, and CD3.
Co-development agreements - Long-term, equity-linked or milestone-based contracts that embed Molecular Partners in partner R&D roadmaps · Scientific collaboration - Joint labs, data-sharing platforms, and co-authored publications to deepen trust · Patient engagement portals - Dedicated “Patients” site offering trial information, consent support, an
Competes in the biopharma sector with unique tetra-specific T cell engagers and radiopharmaceuticals beyond standard treatments.
Limitations of current cancer treatments and the need for more effective, targeted therapeutic solutions.
- Monetize the DARPin discovery service - Offer a “DARPin-as-a-service” model to smaller biotech firms lacking in-house protein engineering
Conduct a pricing simulation for licensing tiers (up-front vs. milestone-heavy) to identify the optimal mix that maximizes cash flow while p · Launch a targeted LinkedIn ad series highlighting DARPin’s multi-specificity benefits to attract new partnership inquiries; set KPI of 10 qu · Map internal R&D processes to AI-enabled design-of-experiments t
- Robust pipeline visibility - The website lists multiple candidates across oncology and infectious disease, with clear clinical-stage mile
Team details not yet available.
No investors recorded yet.